Clinical Research Directory
Browse clinical research sites, groups, and studies.
CD19/79b Bi-specific CAR-T Cell Therapy
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of CD19/79b bi-specific CAR-T cell therapy in patients with CD19 and/or CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/79b bi-specific CAR-T cells and their persistency in patients.
Official title: CD19/79b Bi-specific CAR-T Cells Targeting B Cell Malignancies
Key Details
Gender
All
Age Range
6 Months - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-06-30
Completion Date
2026-06-30
Last Updated
2022-06-29
Healthy Volunteers
No
Conditions
Interventions
bi-4SCAR CD19/79b T cells
Infusion of bi-4SCAR-CD19/79b T cells at 10\^6 cells/kg body weight via IV
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China